Navigation Links
Molecular and protein markers discovered for liver transplant failure from hepatitis C
Date:8/16/2012

dicting early onset liver fibrosis.

Rasmussen's team faced the challenge that no single clinical variable, or combination of clinical variables, could accurately warn that a liver transplant patient was heading for trouble. They decided to look at all of the RNA molecules produced in cells from 111 liver biopsy specimens collected over time from 57 hepatitis C infected patients who had undergone liver transplant surgery. Such a set of molecules is called a transcriptome, a collection of works "written" from the DNA code in response to a viral infection. Her team applied leading-edge mathematical modeling systems to cull patterns of gene expression.

"We were able to identify a molecular signature of gene expression for those patients at risk of developing severe fibrosis in their transplanted livers," Rasmussen said. Significantly, her team also discovered that these alterations in gene expression occur before there is evidence in the liver tissue of disease progression.

"That suggested to us that events that occur during the early stages when the transplanted liver is becoming infected with the patient's hepatitis C virus influence the course of the disease," Rasmussen said. Her team also observed a precursor state a set of conditions that foretold problems ahead that was common for different, severe clinical outcomes. Her team went on to describe the probable cellular network that could be the basis for the initial transition to severe liver disease.

They hope the findings open new avenues in research to delay disease progression and extend the survival of transplanted livers. Both the Rasmussen and the Diamond teams employed systems biology methods to understand the root of post-transplant liver disease recurrence. This approach looks at the complex interactions between pathogens, in this case the hepatitis C virus, and the organism they infect. These interactions are largely studied in their entirety at the scale of
'/>"/>

Contact: Leila Gray
leilag@u.washington.edu
206-685-0381
University of Washington
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Molecular economics: New computer models calculate systems-wide costs of gene expression
2. Scientists discover molecular link between circadian clock disturbances and inflammatory diseases
3. The most celebrated lab manual in molecular biology has been updated and expanded
4. Delving into the molecular mechanism behind deep-sea bacterias pressure tolerance
5. Speed and power of X-ray laser helps unlock molecular mysteries
6. Highlighting molecular clues to the link between childhood maltreatment and later suicide
7. MARC travel award announced for the 2012 GSA Yeast Genetics and Molecular Biology Meeting
8. How bacteria change movement direction in response to oxygen: Molecular interactions unravelled
9. The activity of a bacterial effector protein seen in molecular detail
10. Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats
11. Molecular spectroscopy tracks living mammalian cells in real time as they differentiate
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecular and protein markers discovered for liver transplant failure from hepatitis C
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... the battle against AIDS and a major development in the ... protein that prevents the virus from entering cells. This protein ... that protects cells from viruses, except the man-made version does ... needed to inhibit AIDS. This discovery was published in the ...
... Reducing Emissions from Deforestation and Forest Degradation ... that aims to financially compensate landowners and stewards ... as promoting forest conservation, sustainable forest management and ... and implemented correctly, REDD+ has the potential to ...
... RIVERSIDE, Calif. What are transposable elements, what role do ... they comprise? Is there an explanation for the genetic diversity ... spotted? What is the genetic basis for this spotted trait? ... a free public lecture at 6 p.m., Thursday, April 14, at ...
Cached Biology News:Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3Teaching old genomes new tricks 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... HUYA Bioscience International, a leader in globalizing ... the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology ... in accelerating the development of novel drugs, discovered from ... The agreement provides HUYA with access to and ...
... NephroGenex, Inc., a privately held drug development company, ... the FDA on the design of a new Phase ... nephropathy patients.  This Subpart H program uses a novel ... (SCr), and provides for an accelerated regulatory pathway to ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... third quarter of 2011 and discussed recent business progress. ... past few months highlight the progress at Halozyme on ...
Cached Biology Technology:HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 2HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 3NephroGenex Reaches Agreement with the FDA on a Subpart H Phase 3 Program for Pyridorin™ 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 7
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Integrins Sampler Kit 10g each...
PKC Sampler Kit 10 mu g each...
Biology Products: